COMP <GO>
MDLN vs JNJ // 10Y YIELD & FRED MACRO BETA
Medline Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MDLN 4
— JNJ 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: MDLN
LAST: $32.00 (-1.14%) • MKT CAP: $42.07B
macro-sensitivity
1.11
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 25.50% | -17.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 18.5x | +1.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 2.97% | +0.11 | MDLN | /fcf-yield <GO> |
| Operating Margin | 7.80% | 34.70% | -26.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 6.00% | +5.50 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 5.59 | -3.09 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 62.1 | -31.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.11 | 1.08 | +0.03 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $662.49B | -$620.42B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | JNJ REV | MDLN GROSS % | JNJ GROSS % | MDLN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $94.19B | 26.4% | 67.9% | $1.30B | $19.70B |
| FY 2024 | $25.51B | $88.82B | 27.3% | 69.1% | $1.42B | $19.84B |
| FY 2023 | $23.23B | $85.16B | — | — | $639.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
JNJ // BETA 1.08